Clinical Efficacy of Bevacizumab Combined with Docetaxel Chemotherapy Regimen in the Treatment of Patients with Metastatic Breast Cancer
Author(s): WANG Jianping, QI Longfei, LU Peng, ZENG Hua, DING Yuhai, SHU Ying
Pages: 117-120
Year: 2017 Issue: 2
Journal: Journal of Basic and Clinical Oncology
Keyword: bevacizumab; docetaxel; metastatic breast cancer;
Abstract: Objective To evaluate the clinical efficacy of bevacizumab combined with docetaxel chemotherapy regimen in the treatment of metastatic breast cancer.Methods Eighty-seven patients were randomly divided into the observation group(n=45) and the control group(n=42) according to the random number table method.Forty-five patients of the observation group was treated with bevacizumab combined with docetaxel chemotherapy,42 patients of the control group received capecitabine combined with docetaxel.The total response rate,quality of life,toxicities were compared in the two groups.Results The total response rate in the observation group(64.45%) was significantly higher than that of the control group(40.47%,P<0.05).The improving rate of quality of life in the observation group was significantly higher than that in the control group(P<0.05).The incidence of gstrointestinal reaction syndrome,bone marrow suppression,hand-feet syndrome in the observation group was significantly lower than those in the control group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).Conclusion Bevacizumab combined with docetaxel chemotherapy regimen is effect for patients with metastatic breast cancer,and can significantly improve the quality of life of patients,reduce the incidences of toxicities.
Pages: 117-120
Year: 2017 Issue: 2
Journal: Journal of Basic and Clinical Oncology
Keyword: bevacizumab; docetaxel; metastatic breast cancer;
Abstract: Objective To evaluate the clinical efficacy of bevacizumab combined with docetaxel chemotherapy regimen in the treatment of metastatic breast cancer.Methods Eighty-seven patients were randomly divided into the observation group(n=45) and the control group(n=42) according to the random number table method.Forty-five patients of the observation group was treated with bevacizumab combined with docetaxel chemotherapy,42 patients of the control group received capecitabine combined with docetaxel.The total response rate,quality of life,toxicities were compared in the two groups.Results The total response rate in the observation group(64.45%) was significantly higher than that of the control group(40.47%,P<0.05).The improving rate of quality of life in the observation group was significantly higher than that in the control group(P<0.05).The incidence of gstrointestinal reaction syndrome,bone marrow suppression,hand-feet syndrome in the observation group was significantly lower than those in the control group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).Conclusion Bevacizumab combined with docetaxel chemotherapy regimen is effect for patients with metastatic breast cancer,and can significantly improve the quality of life of patients,reduce the incidences of toxicities.
Related Articles